Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs